Inflammatix is a pioneering molecular diagnostics company focused on transforming the diagnosis of acute infections and sepsis. Utilizing cutting-edge bioinformatics, machine learning, and molecular biology, Inflammatix has developed advanced host-response diagnostic tests that read the body's immune response to identify and differentiate between bacterial and viral infections, as well as non-infectious conditions. This approach addresses significant challenges in traditional diagnostics, which often struggle to provide timely and accurate results for complex conditions like sepsis.

One of Inflammatix's flagship products, the TriVerity™ Acute Infection and Sepsis Test, is designed to help emergency medicine physicians make faster and more accurate treatment decisions by assessing the likelihood of infection and the severity of the patient's condition, potentially improving clinical outcomes.

Inflammatix's diagnostics are still under development and have received recognition, including a breakthrough device designation from the FDA, highlighting their potential impact on healthcare. The company was founded in 2016 and is based in Sunnyvale, California, with a strong team of experts led by CEO Tim Sweeney​